Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0S2GY
|
|||
Former ID |
DNC008906
|
|||
Drug Name |
C[Glu19-Lys23][Gly8]GLP-1(7-37)-NH2
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C147H227N41O45
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCCCN)NC(=O)C(C)NC(=O)C(C)NC(=O)C4CCCCNC(=O)CCC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)N4)CCC(=O)O)CC(C)C)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC6=CN=CN6)N
|
|||
InChI |
1S/C147H227N41O45/c1-16-76(10)118(144(231)166-79(13)123(210)175-101(58-84-61-157-88-37-24-23-36-86(84)88)134(221)177-98(55-73(4)5)135(222)185-116(74(6)7)142(229)174-90(38-25-28-50-148)126(213)160-65-109(197)167-89(41-31-53-156-147(152)153)125(212)158-63-106(151)194)187-136(223)99(56-82-32-19-17-20-33-82)178-132(219)96(45-49-114(204)205)172-130(217)92(39-26-29-51-149)170-122(209)78(12)164-121(208)77(11)165-129(216)91-40-27-30-52-155-107(195)46-42-95(131(218)176-97(54-72(2)3)133(220)171-94(44-48-113(202)203)128(215)161-66-110(198)168-91)173-139(226)103(68-189)181-141(228)105(70-191)182-143(230)117(75(8)9)186-138(225)102(60-115(206)207)179-140(227)104(69-190)183-146(233)120(81(15)193)188-137(224)100(57-83-34-21-18-22-35-83)180-145(232)119(80(14)192)184-111(199)67-162-127(214)93(43-47-112(200)201)169-108(196)64-159-124(211)87(150)59-85-62-154-71-163-85/h17-24,32-37,61-62,71-81,87,89-105,116-120,157,189-193H,16,25-31,38-60,63-70,148-150H2,1-15H3,(H2,151,194)(H,154,163)(H,155,195)(H,158,212)(H,159,211)(H,160,213)(H,161,215)(H,162,214)(H,164,208)(H,165,216)(H,166,231)(H,167,197)(H,168,198)(H,169,196)(H,170,209)(H,171,220)(H,172,217)(H,173,226)(H,174,229)(H,175,210)(H,176,218)(H,177,221)(H,178,219)(H,179,227)(H,180,232)(H,181,228)(H,182,230)(H,183,233)(H,184,199)(H,185,222)(H,186,225)(H,187,223)(H,188,224)(H,200,201)(H,202,203)(H,204,205)(H,206,207)(H4,152,153,156)/t76-,77-,78-,79-,80+,81+,87-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,116-,117-,118-,119-,120-/m0/s1
|
|||
InChIKey |
OCOAZSDHBCONHT-VHWHDJENSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Inhibitor | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.